Organisation paid for research Program year 2025 Source: CMS Open Payments

Sec Clinical Research Robert Garver

Neither a doctor nor a teaching hospital

Research payments

$406,278

97 payments

Through program year 2025, Sec Clinical Research Robert Garver is reported as receiving $406,278 in research payments, across 97 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$14,696	10
2024	Research	$113,262	28
2023	Research	$214,404	48
2022	Research	$52,916	10
2021	Research	$11,000	1

Breakdown

Who paid Research payments · program years 2021–2025

Chiesi USA, Inc. $355,782 73 payments
Genentech, Inc. $50,496 24 payments

Studies the money was for Research payments · program years 2021–2025

A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (Triton) $209,364 38 payments
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) $105,458 22 payments
Roche Cancer Screening Collection Study $50,496 24 payments
A 52-Week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500) Study to Evaluate the Efficacy and Safety of Two Doses of Chf6001 Dpi (Tanimilast) As Add-On to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (Pillar) (Pi $21,664 8 payments
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR) $4,296 3 payments
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR) $4,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.